FOURKITES
Barilla, the world leader in pasta production, has announced that it has achieved 80% visibility into the entire lifecycle of its ocean and road shipments, thanks to leading supply chain visibility provider FourKites. The end-to-end transparency offered by FourKites® allows Barilla to see exactly where its goods are anywhere in the supply chain, as well as when they’ll arrive at their final destination. In the face of military conflict in the Red Sea, disruptive weather events and supply shortages, this comprehensive visibility is critical for Barilla to achieve a resilient supply chain that ensures products get to customers in the most efficient way and with the best service.
Barilla has an intricate logistics operation that includes 30 production sites, 15 of which are in Italy and 15 abroad. Each week, the company moves more than 2,000 loads from Italy to over 120 countries via road and ocean shipments.
Armed with FourKites’ highly accurate, AI-enabled predictive estimated times of arrival (ETAs), Barilla’s customers can confidently plan their operations around scheduled deliveries. Not only are these ETAs updated in transit, but FourKites highlights incorrect planned transit times to ensure that shipments start — and stay — on schedule.
“Before we started using FourKites’ platform, we could only react to an issue when it was too late,” says Davide Busato, Logistic Competence Centre Innovation Project Manager at Barilla. “Now, we react before an issue escalates into a major problem, which saves time while reducing transportation costs and fines. This, in turn, improves our relationships with carriers and customers.”
Ocean shipments are an important part of Barilla’s logistics operation and equal about 10% of its market. Barilla started its collaboration with FourKites by using the company’s over-the-road (OTR) visibility and then expanded coverage to include visibility into all its ocean shipments.
“Freight forwarders had overseen Barilla’s ocean shipments, but it was costly and time-consuming because we had to manually check with carriers on the location of shipments,” continues Busato. “Adding FourKites’ ocean visibility to our setup was an obvious choice, and it’s paid off handsomely. Now, we don’t need to spend time hunting for answers and instead can focus on more important tasks like acting on the FourKites data to improve customer satisfaction.”
“With supply chains under enormous pressure due the conflict in the Red Sea and the drought in the Panama Canal, the need for highly accurate supply chain insights is imperative,” says Marc Boileau, Senior Vice President FourKites EMEA. “We’re delighted Barilla is using FourKites to identify exceptions early, so they can take action and prioritize work based on impact. We look forward to continuing our partnership with them.”
“Our goals with FourKites in 2024 are to track 90% of our shipments, reduce penalties with carriers by 5% and decrease inefficient communication with partners by 10-15%. We’re currently well on our way to meeting these metrics,” Busato says.
FourKites recently announced several enhancements to its next-generation ocean visibility platform, Dynamic Ocean®. By providing better context, clarity and control throughout every ocean shipment, these new features help FourKites users mitigate global disruptions; reduce costly fees like preventable detention and demurrage charges; and exceed customer expectations.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
About Barilla
The Barilla Group Barilla is a family business, not listed on the Stock Exchange, chaired by the brothers Guido, Luca and Paolo Barilla. It was founded by their great-grandfather Pietro Barilla, who opened a bakery in Parma in 1877. Today, Barilla is renowned in Italy and around the world for the excellence of its food products. With its brands – Barilla, Mulino Bianco, Pan di Stelle, Gran Cereale, Harrys, Pavesi, Wasa, Filiz, Yemina and Vesta, Misko, Voiello, Academia Barilla, First, Catelli, Lancia, Splendor, Tolerant, Pasta Evangelists and Back to Nature – it advocates tasty, hearty and wholesome nutrition, inspired by the Mediterranean Diet and the Italian lifestyle. When Pietro opened his shop 146 years ago, the main aim was to make good food. That principle has now become the Barilla way of doing business, with more than 8,700 people working for the company and a supply chain that shares its values and passion for quality. The Group's commitment is to offer people the joy that good, well-made food can bring them, produced with selected ingredients from responsible supply chains, to contribute to a better present and future. Since 1987, a historical archive has been collecting and preserving the company’s 146-year history, now a resource open to all via the portal-museum www.archiviostoricobarilla.com, a testament to the journey of an icon among Made in Italy products and to the changes in Italian society. For further info, visit: www.barillagroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305317743/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
